富马酸替诺福韦二吡呋酯片预防HBV母婴传播的临床效果观察  

Clinical Effect of Tenofovir Disoproxil Fumarate Tablets in Preventing Mother-to-child Transmission of HBV

作　　者：季雯 杨小英 张莉萍[1] JI Wen;YANG Xiao-ying;ZHANG Li-ping(Department of Obstetrics and Gynecology,People's Hospital of Nanfeng County,Nanfeng 344500,Jiangxi,China)

机构地区：[1]南丰县人民医院妇产科,江西南丰344500

出　　处：《医学信息》2023年第17期146-149,共4页Journal of Medical Information

基　　金：抚州市社会发展指导性科技计划项目(编号:202210007248)。

摘　　要：目的观察富马酸替诺福韦二吡呋酯片预防HBV母婴传播的临床效果。方法选取2020年1月-2021年1月在我院产检分娩的42例HBV感染孕妇为研究对象,采用随机数字表法分为对照组和观察组,各组21例。对照组孕妇未接受抗病毒治疗,观察组孕妇给予富马酸替诺福韦二吡呋酯片抗病毒治疗。两组新生儿均给予(0、1、6个月)乙肝疫苗接种,观察两组孕妇孕期并发症发生情况、用药不良反应发生情况、分娩时新生儿体格发育指标(身高、体重)、新生儿9月龄后乙肝5项(乙肝表面抗原、乙肝表面抗体、乙肝E抗原、乙肝E抗体、乙肝核心抗体的阳性率)、新生儿HBV-DNA的阳性率以及新生儿HBV阻断成功率。结果观察组孕妇孕期并发症发生率为19.05%,与对照组的14.29%比较,差异无统计学意义(P>0.05);观察组不良反应发生率为14.29%,与对照组的9.52%比较,差异无统计学意义(P>0.05);观察组分娩时新生儿身高、体重、头围与对照组比较,差异无统计学意义(P>0.05);观察组乙肝表面抗原、乙肝E抗原、乙肝表面抗体、乙肝E抗体、新生儿HBV-DNA的阳性率与对照组比较,差异无统计学意义(P>0.05);观察组乙肝核心抗体的阳性率低于对照组(P<0.05);观察组新生儿HBV阻断成功率为100.00%,与对照组的100.00%比较,差异无统计学意义(P>0.05)。结论富马酸替诺福韦二吡呋酯片联合HBV母婴传播免疫预防可降低乙肝核心抗体的阳性率,预防母婴传播,不良反应发生率小,不会对新生儿体格发育造成影响,具有良好的母婴安全性,值得临床应用。Objective To observe the clinical effect of tenofovir disoproxil fumarate tablets in preventing mother-to-child transmission of HBV.Methods A total of 42 pregnant women with HBV infection who were examined and delivered in our hospital from January 2020 to January 2021 were selected as the research objects.They were divided into control group and observation group by random number table method,with 21 pregnant women in each group.The pregnant women in the control group did not receive antiviral therapy,and the pregnant women in the observation group were given antiviral therapy with tenofovir disoproxil fumarate tablets.The newborns of two groups were given(0,1,6 months)hepatitis B vaccine inoculation.The incidence of complications during pregnancy,the incidence of adverse drug reactions,the physical development index(height,weight)of newborns during delivery,the five items of hepatitis B after 9 months of age(hepatitis B surface antigen,hepatitis B surface antibody,hepatitis B E antigen,hepatitis B E antibody,hepatitis B core antibody positive rate),the positive rate of neonatal HBV-DNA and the success rate of neonatal HBV blocking were observed.Results The incidence of pregnancy complications in the observation group was 19.05%,which was compared with 14.29%in the control group,the difference was not statistically significant(P>0.05).The incidence of adverse reactions in the observation group was 14.29%,which was compared with 9.52%in the control group,the difference was not statistically significant(P>0.05).There was no significant difference in neonatal height,weight and head circumference between the observation group and the control group(P>0.05).There was no significant difference in the positive rate of hepatitis B surface antigen,hepatitis B E antigen,hepatitis B surface antibody,hepatitis B E antibody and neonatal HBV-DNA between the observation group and the control group(P>0.05).The positive rate of hepatitis B core antibody in the observation group was lower than that in the control group(P<0.05).Con

关 键 词：富马酸替诺福韦二吡呋酯片 HBV 免疫预防 

分 类 号：R714.251[医药卫生—妇产科学]